Premium
Efficacy of liposome‐encapsulated 4‐n‐butylresorcinol and resveratrol cream in the treatment of melasma
Author(s) -
Kwon SoonHyo,
Yang Ji Hoon,
Shin JungWon,
Park KyoungChan,
Huh ChangHun,
Na JungIm
Publication year - 2020
Publication title -
journal of cosmetic dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.626
H-Index - 44
eISSN - 1473-2165
pISSN - 1473-2130
DOI - 10.1111/jocd.13080
Subject(s) - melasma , medicine , dermatology , adverse effect , randomized controlled trial
Backgrounds We previously reported the efficacy of 0.1% 4‐n‐butylresorcinol (4nBR) cream in the treatment melasma and synergistic effect of 4nBR and resveratrol (RSV) to inhibit melanogenesis in vitro. Aims To evaluate efficacy and safety of a cream which contains liposome‐encapsulated 4nBR and RSV in the treatment of melasma. Patients/Methods A total of 21 female patients with melasma were treated with the cream for 4 weeks. At baseline, week 2, and week 4, melanin index (MI) of the lesional and preauricular nonlesional skin was measured and two blinded, independent dermatologists assessed the overall severity by 5‐point scale. Results The lesional MI was significantly decreased at weeks 2 and 4 compared with the baseline while no significant change in the nonlesional MI was observed throughout the study. The mean investigator's global assessment score was also significantly improved at weeks 2 and 4. In patient's self‐assessment, 8 (38.1%) and 11 (52.3%) patients answered moderate to significant improvement in their melasma at weeks 2 and 4, respectively. No serious adverse events were reported. Conclusion The cream containing liposome‐encapsulated 4nBR and RSV was shown to be effective and safe for the treatment of melasma with its effect appearing as early as 2 weeks.